Atezolizumab: tested in a combination

244 studies: another drug in the study is under test too. Page 3 of 3. Open to participants first (57), then studies with results posted, then the rest; newest registration first within each.

• A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell CarcinomaWithdrawnNCT03693573Phase 3Report a problem
• Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase InhibitorsStatus unknownNCT03647956Phase 2Report a problem
• Phase II Study of Atezolizumab + Bevacizumab in Endometrial CancerActive, not recruitingNCT03526432Phase 2Report a problem
• Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With RadiotherapyActive, not recruitingNCT03474094Phase 2Report a problem
• Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)Active, not recruitingNCT03448835Phase 2Report a problem
• BEACON - ABC in Recurrent Platinum Resistant HGSOCCompletedNCT03363867Phase 2Report a problem
• Atezolizumab Monotherapy vs Atezolizumab Plus Cobimetinib in Liver Metastases From Colorectal CancerWithdrawnNCT03340558Phase 2Report a problem
• Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical CancerActive, not recruitingNCT03340376Phase 2Report a problem
• Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell LymphomaActive, not recruitingNCT03321643Phase 1Report a problem
• Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory LymphomasCompletedNCT03276468Phase 2Report a problem
• Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast CancerActive, not recruitingNCT03202316Phase 2Report a problem
• A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT03178552Phase 2/3Report a problem
• Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain MetastasesActive, not recruitingNCT03175432Phase 2Report a problem
• Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsActive, not recruitingNCT03170960Phase 1Report a problem
• NCT Neuro Master Match - N²M² (NOA-20)CompletedNCT03158389Phase 1/2Report a problem
• A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)Active, not recruitingNCT03148418Phase 3Report a problem
• AssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast CancerTerminatedNCT03147040Phase 2Report a problem
• Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast CancerActive, not recruitingNCT03125928Phase 2Report a problem
• A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast CancerCompletedNCT03101280Phase 1Report a problem
• A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder CancerCompletedNCT03093922Phase 2Report a problem
• Atezolizumab and Bevacizumab in Treating Patients With Rare Solid TumorsActive, not recruitingNCT03074513Phase 2Report a problem
• Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate CancerCompletedNCT03024216Phase 1Report a problem
• Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT StudyActive, not recruitingNCT02997228Phase 3Report a problem
• Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic TumoursCompletedNCT02992912Phase 2Report a problem
• A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder CancerActive, not recruitingNCT02989584Phase 1/2Report a problem
• Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal CancerTerminatedNCT02982694Phase 2Report a problem
• Carboplatin-cyclophosphamide Combined With AtezolizumabCompletedNCT02914470Phase 1Report a problem
• Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant MelanomaCompletedNCT02902029Phase 2Report a problem
• ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+BevacizumabCompletedNCT02891824Phase 3Report a problem
• Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other TumorsCompletedNCT02876224Phase 1Report a problem
• Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter SyndromeActive, not recruitingNCT02846623Phase 2Report a problem
• Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway InhibitorCompletedNCT02814669Phase 1Report a problem
• Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian CancerCompletedNCT02659384Phase 2Report a problem
• Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast CancerCompletedNCT02605915Phase 1Report a problem
• Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung CancerWithdrawnNCT02495636Phase 2Report a problem
• A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)CompletedNCT02431208Phase 1Report a problem
• Deciphering Antitumour Response and Resistance With INtratumour HeterogeneityCompletedNCT02314481Phase 2Report a problem
• Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VCTerminatedNCT02303951Phase 2Report a problem
• A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell LymphomaCompletedNCT02220842Phase 1Report a problem
• A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02013219Phase 1Report a problem
• Study of Atezolizumab in Combination With Cobimetinib in Participants With Locally Advanced or Metastatic Solid TumorsCompletedNCT01988896Phase 1Report a problem
• Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast CancerActive, not recruitingNCT01898117Phase 2Report a problem
• Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck CancerSuspendedNCT01810913Phase 2/3Report a problem
• A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic MelanomaCompletedNCT01656642Phase 1Report a problem

← Atezolizumab